Summary
Regeneron Pharmaceuticals, Inc. (REGN) reported its second-quarter and first-half financial results for the period ending June 30, 2006. The company continues to operate at a loss, with a net loss of $23.6 million for the quarter and $44.0 million for the first six months of the year. Revenue increased year-over-year driven by higher contract research and development revenue from its collaboration with sanofi-aventis, primarily related to the VEGF Trap program, and increased contract manufacturing revenue from Merck. Despite revenue growth, operating expenses, particularly research and development, remain significant, contributing to the ongoing net loss. The company's balance sheet shows a decrease in cash and cash equivalents from the prior year-end, offset by an increase in marketable securities. Long-term debt remains substantial at $200 million. Management highlighted progress in its key development programs, including VEGF Trap for oncology and eye diseases, and IL-1 Trap for inflammatory diseases. Significant investment continues in these pipeline assets, which is expected to result in continued substantial losses for the foreseeable future. The company believes its existing capital resources are sufficient to meet operating needs through mid-2008, but acknowledges the potential need for additional financing.
Key Highlights
- 1Regeneron reported a net loss of $23.6 million for Q2 2006 and $44.0 million for the first six months of 2006.
- 2Total revenue increased to $19.3 million in Q2 2006 and $37.5 million for the first six months of 2006, driven by higher contract research/development and manufacturing revenues.
- 3Revenue from the sanofi-aventis collaboration for VEGF Trap increased significantly due to expense reimbursements and recognition of deferred revenue from an up-front payment.
- 4Operating expenses decreased year-over-year to $43.5 million in Q2 2006 and $83.4 million for H1 2006, attributed partly to lower headcount following workforce reductions.
- 5Cash and cash equivalents decreased to $115.0 million as of June 30, 2006, from $184.5 million at December 31, 2005.
- 6The company continues to invest heavily in research and development, with its lead programs being VEGF Trap (oncology and eye diseases) and IL-1 Trap (inflammatory diseases).
- 7Regeneron anticipates needing substantial funding for continued R&D and believes existing capital is sufficient through mid-2008, with potential for additional financing.